- Dies positioniert Curium als führenden Hersteller des Isotops Lu–177
- Integration innovativer [...] Read more »
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
- Positions Curium as leading manufacturer of Lu–177 isotope
- Brings innovative R&D expertise and pipeline to Curium
- Enhances Curium’s SPECT & PET geographical [...] Read more »
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
- Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T
- Builds on long–standing [...] Read more »